- Home
- LRMR vs DCTH Comparison
LRMR vs DCTH Comparison
Compare LRMR & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRMR
- DCTH
- Stock Information
- Founded
- LRMR N/A
- DCTH 1988
- Country
- LRMR United States
- DCTH United States
- Employees
- LRMR N/A
- DCTH N/A
- Industry
- LRMR Biotechnology: Pharmaceutical Preparations
- DCTH Medical/Dental Instruments
- Sector
- LRMR Health Care
- DCTH Health Care
- Exchange
- LRMR Nasdaq
- DCTH Nasdaq
- Market Cap
- LRMR 332.1M
- DCTH 388.3M
- IPO Year
- LRMR N/A
- DCTH N/A
- Fundamental
- Price
- LRMR $3.45
- DCTH $8.62
- Analyst Decision
- LRMR Strong Buy
- DCTH Strong Buy
- Analyst Count
- LRMR 7
- DCTH 5
- Target Price
- LRMR $16.71
- DCTH $22.60
- AVG Volume (30 Days)
- LRMR 1.8M
- DCTH 1.3M
- Earning Date
- LRMR 11-05-2025
- DCTH 11-04-2025
- Dividend Yield
- LRMR N/A
- DCTH N/A
- EPS Growth
- LRMR N/A
- DCTH N/A
- EPS
- LRMR N/A
- DCTH 0.03
- Revenue
- LRMR N/A
- DCTH $79,603,000.00
- Revenue This Year
- LRMR N/A
- DCTH $135.11
- Revenue Next Year
- LRMR N/A
- DCTH $36.30
- P/E Ratio
- LRMR N/A
- DCTH $250.39
- Revenue Growth
- LRMR N/A
- DCTH 251.54
- 52 Week Low
- LRMR $1.61
- DCTH $8.39
- 52 Week High
- LRMR $9.50
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- LRMR 39.35
- DCTH 30.11
- Support Level
- LRMR $3.16
- DCTH $9.15
- Resistance Level
- LRMR $4.50
- DCTH $10.03
- Average True Range (ATR)
- LRMR 0.30
- DCTH 0.67
- MACD
- LRMR -0.10
- DCTH -0.21
- Stochastic Oscillator
- LRMR 24.09
- DCTH 5.71
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.